Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death

USRE48992E1 · kind E1 · reissue

Assignee

• Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) · DE

Inventors

• Marcus Conrad · Munich, DE
• Joel Schick · Munich, DE
• Bettina Proneth · Munich, DE
• Peter Sennhenn · Munich, DE

Key dates

• Filing date: Oct 31, 2019
• Grant date: Mar 29, 2022
• Expiry date: Oct 31, 2039

Classification

• Technology area (CPC —): General

Abstract

The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.